Nanette Alexander, APRN
Adult Health · Glastonbury, CTNPI 1568449262
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 653 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 53 manufacturers reported payments, led by GSK at 27.9% of the total. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 653 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$924
- Boehringer Ingelheim$673
- Takeda Pharmaceuticals U.S.A., Inc.$527
- plus $4K from 47 others
What the payments were for
- Consulting fees$1,2009%
- Food & beverage$12,55991%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,770 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $175,081 |
| JardianceEmpagliflozin | 84 | $100,021 |
| XolairOmalizumab | 14 | $77,763 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $68,107 |
| FarxigaDapagliflozin Propanediol | 46 | $59,809 |
| TezspireTezepelumab-Ekko | 12 | $53,092 |
| RybelsusSemaglutide | 42 | $49,728 |
| EliquisApixaban | 33 | $49,096 |
| XareltoRivaroxaban | 23 | $27,224 |
| OxycontinOxycodone Hcl | 21 | $25,392 |
| MyrbetriqMirabegron | 26 | $21,065 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $20,896 |
| JanuviaSitagliptin Phosphate | 13 | $19,774 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $19,206 |
| BelsomraSuvorexant | 26 | $17,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $924 | $224,809152 claims |
| AstraZenecaFarxiga, Tezspire, Symbicort, Bevespi Aerosphere | $1,647 | $131,382103 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $673 | $116,880100 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,842 | $104,252115 claims |
| PfizerEliquis | $477 | $49,09633 claims |
| MerckJanuvia, Belsomra, Dulera | $94 | $41,81850 claims |
| AbbVieCreon, Synthroid, Linzess | $2,028 | $27,581102 claims |
| Johnson & JohnsonXarelto | $91 | $27,22423 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $21,06526 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $527 | $14,23018 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $2,546271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in Glastonbury
- Jennifer KaranianGlastonbury$9K
- Kelly HeilmanGlastonbury$7K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.